Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ: SRRK) announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET.
A live and archived webcast will be available on the company’s investor relations website.
Scholar Rock (NASDAQ: SRRK) announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 11:40 a.m. ET.
A live and replay webcast will be accessible via the Investors section of the company’s website.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards for an aggregate 38,481 common shares to six new employees under its 2022 Inducement Equity Plan.
The grants include stock options for 12,061 shares at a $48.35 exercise price and 26,420 restricted stock units, with multi-year vesting tied to continued service.
Scholar Rock (NASDAQ: SRRK) reported Q1 2026 results and regulatory progress for apitegromab. The FDA accepted the apitegromab BLA with a PDUFA date of Sept 30, 2026, covering two U.S. fill-finish sites. Catalent reinspection is complete; facility classification is expected within 90 days.
The second fill-finish site is on track to supply commercial product in early Q3 2026. Scholar Rock reported cash, cash equivalents, and marketable securities of $479.9 million as of March 31, 2026, reflecting a $100.0 million debt draw and $98.0 million net ATM proceeds. Q1 net loss was $105.5 million.
Scholar Rock (NASDAQ: SRRK) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on May 12, 2026 at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast will be available via the company’s Investors "Events and Presentations" page, with a replay available for ~90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards totaling 89,304 shares to nine newly hired employees on April 17, 2026 under its 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards comprise 38,331 inducement stock options (exercise price $49.52) and 50,973 inducement restricted stock units. Options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments, all subject to continued service.
Scholar Rock (NASDAQ: SRRK) will report first quarter 2026 financial results on Thursday, May 7, 2026 before markets open. A live conference call and webcast with management will start at 8:00 a.m. ET, with an archived replay available on the investor website for ~90 days.
Telephone participation requires advance registration; registrants receive a confirmation email with dial‑in instructions.
Scholar Rock (NASDAQ: SRRK) resubmitted the apitegromab BLA to the FDA on March 31, 2026, including Catalent Indiana and a second U.S. fill-finish facility. The company expects FDA acceptance within 30 days and a PDUFA action date in late September 2026.
Updates were limited in scope, mainly a standard safety update; EMA MAA review is proceeding with a decision anticipated mid-2026. Apitegromab retains Fast Track, Priority Review, Orphan Drug, Rare Pediatric Disease, and EMA PRIME designations.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 60,655 shares to five newly hired employees on March 13, 2026. Awards include inducement stock options for 24,506 shares at an exercise price of $44.23 and inducement restricted stock units for 36,149 shares.
Options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments. Awards are governed by the company’s 2022 Inducement Equity Plan under Nasdaq Rule 5635(c)(4).
Scholar Rock (NASDAQ:SRRK) reported Q4 2025 net loss of $91.0M and FY 2025 net loss of $377.9M, with no revenue. The company had $367.6M in cash and marketable securities as of December 31, 2025, and secured a debt facility of up to $550M to support apitegromab commercialization.
Apitegromab BLA resubmission is planned after a successful FDA reinspection; FDA and EMA milestones and commercial launch activities are expected through 2026.